Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Gains from Sales and Divestitures (2023 - 2025)

Historic Gains from Sales and Divestitures for SAB Biotherapeutics (SABS) over the last 3 years, with Q3 2025 value amounting to $12544.0.

  • SAB Biotherapeutics' Gains from Sales and Divestitures fell 5997.83% to $12544.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $12544.0, marking a year-over-year decrease of 5997.83%. This contributed to the annual value of $22709.0 for FY2024, which is 7719.26% up from last year.
  • Per SAB Biotherapeutics' latest filing, its Gains from Sales and Divestitures stood at $12544.0 for Q3 2025, which was down 5997.83% from $8364.0 recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Gains from Sales and Divestitures peaked at $106250.0 during Q3 2023, and registered a low of $4183.0 during Q1 2025.
  • Its 3-year average for Gains from Sales and Divestitures is $32334.7, with a median of $22843.5 in 2024.
  • Per our database at Business Quant, SAB Biotherapeutics' Gains from Sales and Divestitures surged by 7719.26% in 2024 and then crashed by 8179.56% in 2025.
  • SAB Biotherapeutics' Gains from Sales and Divestitures (Quarter) stood at $12816.0 in 2023, then soared by 77.19% to $22709.0 in 2024, then tumbled by 44.76% to $12544.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $12544.0 for Q3 2025, versus $8364.0 for Q2 2025 and $4183.0 for Q1 2025.